ObjectiveTo investigate the homology and resistant mechanism of vancomycin-resistant Enterococci (VRE) isolates.
目的探讨万古霉素耐药肠球菌(VRE)的同源性及主要耐药机制。
The use of oral vancomycin to treat pseudomembranous colitis contributed to the emergence of vancomycin-resistant enterococci51.
口服万古霉素用于治疗伪膜性肠炎促使了耐万古霉素肠球菌株的出现。
Abstract: Objective To understand the susceptibility phenotype and genetic characteristics of vancomycin-resistant Enterococci (VRE).
摘要：目的研究万古霉素耐药肠球菌(VRE)的耐药表型和基因特性。
CONCLUSIONS We should enhance the management of glycopeptide application and use the drug reasonably, in order to postpone the emergence of vancomycin-resistant S. aureus.
结论应加强对糖肽类抗生素使用的管理，合理用药，以延缓耐万古霉素葡萄球菌的产生。
Objectives: Through analyzing the phenotype and genotype of VRE, to investigate epidemiology of vancomycin-resistant enterococci strains (VRE) for instructing rational use of antibiotics in clinic.
目的：对耐万古霉素的肠球菌进行表型及基因型分析，了解临床耐万古霉素肠球菌(VRE)的流行状况，指导临床合理使用抗生素。
Vancomycin-resistant enterococci(VRE); Resistance; Rational drug use.
耐万古霉素的肠球菌；耐药性；合理用药。
The detectable rate of Vancomycin-Resistant Enterococci (VRE) was 10.00%.
万古霉素耐药肠球菌（VRE）检出率为10.00%。
An actinomycetes strain AR1148 was isolated from soil and its metabolites could inhibit the growth of VRE (vancomycin resistant Enterococcus).
从土壤中分离得到一株放线菌ar 1148，其代谢产物对万古霉素耐药肠球菌有较明显的抑菌活性。
CNS resistant to vancomycin were not found.
未发现对万古霉素耐药的CNS。
To investigate the changes in pathogenicity, toxicity and pathological features of Staphylococcus aureus resistant to vancomycin for clinical reference in diagnosis and treatment.
目的了解金葡菌对万古霉素耐药后毒力和致病性变化规律及病变特征，为临床正确诊断和合理治疗奠定基础。
AIM: to study the effect of levofloxacin, vancomycin, rifampin, azithromycin, tobramycin and chloramphenicol concentration on selection of resistant mutants of staphylococcus aureus ATCC29213.
目的：了解左氧氟沙星、万古霉素、利福平、氯霉素、妥布霉素、阿齐霉素在不同浓度时对金黄色葡萄球菌atcc 29213耐药突变株选择的影响。
Staphylococcus and enterococcus resistant to vancomycin were not found.
尚未发现耐万古霉素的葡萄球菌株及肠球菌株。
No strain of Staphylococcus and Enterococcus resistant to vancomycin was found.
未发现耐万古霉素的葡萄球菌和肠球菌。
Part of Enterococcus strains resistant to vancomycin.
肠球菌中部分菌株耐万古霉素。
No vancomycin resistant strains detected.
未发现万古霉素耐药株。
The heterogeneously resistant staphylococci to vancomycin may be a significant cause of the failure of vancomycin in the treatment of methicillin-resistant staphylococcus infections.
对万古霉素异质性耐药可能是万古霉素治疗医院内耐甲氧西林葡萄球菌感染失败的重要原因之一。
No vancomycin resistant Staphylococcus or Enterococcus was detected.
未发现耐万古霉素的葡萄球菌和肠球菌。
In recent years, vancomycin sensitivity of the Staphylococcus aureus has been dropped gradually in the world, and the medicine-resistant strains appear one after another in various countries.
近年来金黄色葡萄球菌对万古霉素的敏感性逐渐下降，并在各国相继出现了耐药菌株。
Vancomycin, a glycopeptide antibiotic, was used as the first-line drug in treatment of serious infections caused by methicillin-resistant Staphylococcus aureus (MRSA).
万古霉素是目前临床上用于治疗由甲氧西林耐药金葡菌(MRSA)引起的严重感染疾病的首选药物。
Vancomycin Resistant Staphylococcuswas not found.
尚未发现耐万古霉素菌株。
Vancomycin is the most potent antimicrobial agent against gram positive organisms with the resistant rate of Enterococcus faecalis at 1.7%.
革兰阳性球菌中万古霉素抗菌活性最强，粪肠球菌对万古霉素耐药率为1.7%。
Vancomycin is the most potent antimicrobial agent against gram positive organisms with the resistant rate of Enterococcus faecalis at 1.7%.
革兰阳性球菌中万古霉素抗菌活性最强，粪肠球菌对万古霉素耐药率为1.7%。
应用推荐